ESR1 and breast carcinoma: Overall, these properties of FLTX2 make this derivative a potential heir of TX, as a pharmacophore endowed with the ability to specifically bind ER and to antagonize ER activation in estrogen-dependent breast cancer cells, which upon appropriate irradiation would undergo uncontrolled oxidative stress.